Goodwin C Rory, Yanamadala Vijay, Ruiz-Valls Alejandro, Abu-Bonsrah Nancy, Shankar Ganesh, Sankey Eric W, Boone Christine, Clarke Michelle J, Bilsky Mark, Laufer Ilya, Fisher Charles, Shin John H, Sciubba Daniel M
Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
World Neurosurg. 2016 Jul;91:510-517.e4. doi: 10.1016/j.wneu.2016.04.026. Epub 2016 May 13.
Hepatocellular carcinoma (HCC) frequently metastasizes to the spine. The impact of medical and/or surgical intervention on overall survival has been examined in a limited number of clinical studies, and herein we systematically review these data.
We performed a literature review using PubMed, Embase, CINAHL, and Web of Science to identify articles that reported survival, clinical outcomes, and/or prognostic factors associated with patients diagnosed with spinal metastases. The methodologic quality of each review was assessed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses tool.
There were 26 articles (152 patients) that met the inclusion criteria and were treated with either surgery, radiotherapy, chemotherapy, and/or observation. There were 3 retrospective cohort studies, 17 case reports, 5 case series, and 1 longitudinal observational study. Of the patients with known overall survival after diagnosis of spinal metastasis, survival at 3 months, 6 months, 1 year, 2 years, and 5 years was 95.2%, 83.0%, 28.6%, 2.0%, and 1.4%, respectively. The median survival after diagnosis of the metastasis was 0.7 months in the patients who received no treatment, 7 months in the patients treated with surgical intervention alone, 6 months for patients who received chemotherapy and/or radiation, and 13.5 months in the patients treated with a combination of surgery and medical management. All other clinical or prognostic parameters were of low or insufficient strength.
Patients diagnosed with HCC spinal metastasis have a 10.6-month overall survival. Further analysis of patients in prospective controlled trials will be essential to the development of treatment algorithms for these patients in the future.
肝细胞癌(HCC)常转移至脊柱。在少数临床研究中已探讨了医学和/或手术干预对总生存期的影响,在此我们对这些数据进行系统回顾。
我们使用PubMed、Embase、CINAHL和Web of Science进行文献回顾,以确定报告与诊断为脊柱转移患者相关的生存期、临床结局和/或预后因素的文章。使用系统评价和Meta分析的首选报告项目工具评估每项综述的方法学质量。
有26篇文章(152例患者)符合纳入标准,接受了手术、放疗、化疗和/或观察治疗。有3项回顾性队列研究、17例病例报告、5个病例系列和1项纵向观察性研究。在诊断为脊柱转移后已知总生存期的患者中,3个月、6个月、1年、2年和5年的生存率分别为95.2%、83.0%、28.6%、2.0%和1.4%。转移诊断后的中位生存期在未接受治疗的患者中为0.7个月,仅接受手术干预的患者中为7个月,接受化疗和/或放疗的患者中为6个月,接受手术和药物治疗联合的患者中为13.5个月。所有其他临床或预后参数的强度低或不足。
诊断为HCC脊柱转移的患者总生存期为10.6个月。未来对前瞻性对照试验中的患者进行进一步分析对于制定这些患者的治疗方案至关重要。